Ottawa woman facing blindness pleads with province to cover sight-saving procedure
Optometric assistant Michelle Boich, 33, recently diagnosed with keratoconus
An Ottawa woman who has devoted her career to helping others improve their vision has discovered she needs a costly eye procedure — and risks going blind without it.
Michelle Boich, 33, is a certified optometric assistant. She recently found out she has keratoconus, a degenerative eye disease which causes the cornea — the clear, front part of the eye — to thin and change shape.
I shouldn't have to fight for my vision. Everyone should get the same chance.- Michelle Boich
If left untreated, Boich could slowly lose her sight. Once that happens, the province will pay for corneal transplant surgery.
There is a procedure that could prevent Boich's condition from worsening, but corneal collagen cross linking, or CXL, isn't covered under Ontario's health insurance plan (OHIP), and can cost thousands of dollars.
Six other provinces and territories, including Quebec, pay for the procedure.
The Ontario government has spent millions of dollars studying whether it should cover CXL under OHIP, but has yet to make a decision.
- NDP, Tories slam the Wynne government for not funding sight-saving surgery
- Boy told he'd have to go blind before health system would pay for sight-saving surgery
Under a pilot project that began in Toronto in December 2012 and ended in March 2015, Ontario funded hundreds of CXL surgeries. Even after the project ended, the government continued to spend about $800,000 per year to treat eligible patients in several cities — Toronto, Ottawa, Kingston, London and Sudbury.
However, there are strict requirements to qualify for the paid procedure, and Boich has been told that because she had amblyopia as a child — commonly called lazy eye — she's unlikely to get into the program at the Ottawa Hospital Eye Institute.
'Put yourself in my shoes'
That's money Boich doesn't have, but she said she's willing to go into debt to save her right eye.
"Put yourself in my shoes," said Boich, who has two daughters as well as two step-children. "If you could never see your family again — your spouse, your kids, the people that are important to you — how would you feel, that the government doesn't see the importance to cover this surgery?"
Boich has always struggled with her eyesight. She was nearly blind in one eye as a child and wore a patch under her big, red glasses. Through a lot of hard work she gained strength in her weak eye and eventually gained 20/30 vision.
She said it was that childhood experience that made her want to help others improve their eyesight.
It was Boich's optometrist, and boss, who discovered her keratoconus during a routine eye exam two months ago.
"It is a concern," said optometrist Dr. Corina Buettner, who owns Nuvo Eye Centre. "It's scary to think of what the possibilities are. I'm glad we found it at this point, and we can do things about it."
Study urged funding of CXL
Boich is petitioning the province to cover CXL under OHIP, and has so far collected 25,000 signatures online.
A study was completed after the official end of the provincial pilot project and handed over to the government in December 2016.
Dr. Sherif El-Defrawy is the ophthalmologist-in-chief at Kensington Eye Institute, which oversaw the project. He says the report shows evidence CXL is effective on patients with keratoconus or other conditions where there is progression of corneal warping.
"Treating with cross-linking stops this progression completely or slows it down significantly," said El-Defrawy. "It's a value to patients with this condition. And patients with this condition in Ontario should be offered this treatment."
More than a year later the government is still reviewing those findings.
Some ophthalmologists unaware of program
There are signs the interim program isn't widely known even among ophthalmologists, however.
"I haven't told a patient there is a program, because I didn't know about it actually," said Dr. Mohammed Taha, a cornea specialist at Icare Surgical and Optical Centre.
"I think it should be advertised more. I think every ophthalmologist should know about it and give that option to the patient."
Taha performs CXL, and said it's an effective and safe procedure that preserves eyesight and avoids the need for transplant surgery. It's minimally invasive and can be performed in about 45 minutes in an office instead of an operating room.
The procedure should be covered, he said.
"I don't think it's fair for patients to pay for a medically needed procedure to prevent them from losing their sight," Taha said. "I think it should be covered by OHIP because it's preventing a disease from getting worse."